Old Wegmaster from Yahoo Board
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I I could not agree more ??????
Complaining, shooting oneself in the foot. This board. If I were reading these posts and hear all of it and then the complaint ends with sell for $15/ share or whatever. Not quite a promotion. Can we try and stick with what we do have going more than what we don't. I realize it is therapy for those who are down.
It is a long slow process, unfortunately. Each milestone steady and ADXS hits the bulleeye in its trials. Cash on hand and current cash deals should let us ride until science shows its full bloom. IMO Then Pay Day. I will be there.
Poison Pill. Shares can be protection from hostile takeover, insurance of many kinds, optional, but prudent to have the tool. Fundamental, but a big negative perception. I pray never used and we can go the distance with our 70 mill, plus future cash flow. btw....The BOD who left seemed to not do much for us in the past. Tom Ridge big name, seemed to do zippo for us, for example.
James, you have been quiet. You keep it pertinent.
I am curious if you have more thoughts about this:
[color=red]Results
Ten patients were treated including one with N2 and four with N3 disease. Two patients had grade 3 acute toxicities following the initial dose of ADXS11-001 including chills/rigors (n = 2), back pain (n = 1), and hyponatremia (n = 1). All ADXS11-001 toxicities occurred within 24 hours of administration. There was no apparent increase in chemoradiation toxicities or myelosuppression. One patient had a grade 5 cardiopulmonary event shortly after beginning 5-FU treatment. All 9 assessable patients had complete clinical responses by sigmoidoscopy. Eight of 9 patients (89%) are progression-free at a median follow-up of 42 months.
Conclusions
Preliminary data shows that ADXS11-001 can be safely administered with standard chemoradiation for anal cancer. Further studies of listeria-based immunotherapy with radiation are warranted.[color=red]
My bet is Amgen...
Can you translate this for me, in terms of results?
February 2018 (Final data collection date for primary outcome measure)
" Dog Dexter More than five years after Dexter received this immunotherapy, he’s still alive and cancer-free."
ADXS to the rescue!
We need some news, even small. It seemed we always had a new deal every couple of months...now quiet. Yes, we have many things in the hopper, but come on ADXS!
But not one mention of ADVAXIS -In this case, the immunotherapy—developed by UPenn’s Yvonne J. Paterson, Ph.D., while being funded by the Cancer Research Institute (CRI)—involves genetically modified bacteria and takes advantage of the fact that about half of all osteosarcomas have abnormally high levels of a protein called HER2, a protein also associated with cancers of the breast, stomach, and ovaries in humans.
In 2012, an Old English Sheepdog named Dexter (below) became one of the first dogs treated with this new approach (along with chemotherapy and amputation) in a Penn Vet clinical trial led by Mason. By injecting the HER2-positive bacteria into Dexter, doctors taught his immune system to seek out and destroy anything that looked like the bacteria, including the HER2-positive tumor cells.
Dog Dexter
More than five years after Dexter received this immunotherapy, he’s still alive and cancer-free.
As the trial continued, the immunotherapy’s benefits became clear. The dogs that received it were more than twice as likely to survive at least two years compared to those that received only the standard treatment. While historically only 28% of dogs with osteosarcoma survive at least two years, 67% of those treated with this immunotherapy reached that mark.
Based on the remarkable results in dogs, clinical trials are now in progress to see if this immunotherapy approach will work against osteosarcoma in children, who still have few promising options.
“I don’t think we’re ever going back”[color=red][/color]
Bank of Montreal added over 400,000 shares this month, that in itself is notable!
I am on my second round. Made like 130K first time, long term hold. I miss the Yahoo Board. I think my average is around 9, so I am down. Patience is a virtue. Europe please. I believe the puppies will open the doors.
Dr. Ghamande on the AIM2CERV Trial in Cervical Cancer
some PR
http://www.onclive.com/onclive-tv/dr-ghamande-on-the-aim2cerv-trial-in-cervical-cancer
I would expect validation of PETX to bolster SP....Shorts are holding us again.
Hovacare, Are you the author of the Seeking Alpha - Advaxis 2018: A New Year, A New Hope ?
Well Done, if true.
Dinner, I guess we should be happy he is a significant shareholder:
"But Alex Denner has been credited as the power behind the throne, a key player in the turnaround story of several top life sciences companies
Combining knowledge of the business with a clear connection to the science involved, Denner has created the template for the modern-day biotech turnaround story.
"Alex actually understands the science--and how to build that into a business," ex-con and ImClone founder Sam Waksal told Bloomberg. "When a company is broken, he knows what should be done to fix it."
I cannot help but comment that ADXS is saving money on payroll without a CEO and CMO ;)
btw...anyone know if shorts activity is down? bid/ ask tight, looks normal with upward pressure. I feel positive trend.
Everyone Keep Faith... I am all in too. I like below points from Zach Hartman
Just to start the year...something we waited for over 4 years for on
Advaxis's first revenue stream?
ADXS-HER2 for the treatment of canine osteosarcoma
"...arguably most important, benefit for ADXS is the validation of the technology. The trial in dogs that led to the approval of the listeria-based therapy showed a near doubling of the median survival time. This represents perhaps the most impactful demonstration of efficacy that we've seen for a listeria-based therapy in cancer, and it definitely bodes well for the entire concept of listeria-based immunotherapy.
This approval should be a big shot in the arm that was needed after Aduro decided to exit the bulk of its listeria-based developmental programs.Some anticipated news has also come down the grapevine regarding one of ADXS's oldest commercial partners, Aratana Therapeutics (PETX). The two companies entered into a clinical collaboration in 2014, wherein ADXS licensed, among other agents, ADXS-HER2 for the treatment of canine osteosarcoma.
Well, it appears as though this collaboration has finally borne fruit, as PETX announced that the USDA has granted conditional licensure, which means they will be able to start selling the product for veterinary purposes.
For ADXS, this serves up two big benefits. One, they are entitled to undisclosed milestone payments, likely in the one or two million dollar range at most. In addition, they are eligible for royalties of up to 10% from sales of the licensed drug. Likely this won't amount to a huge boon in terms of cash, as the upper limit for market penetration is some 10,000 dogs diagnosed with osteosarcoma a year, and many won't receive this treatment. However, every little bit of revenue will count mightily for ADXS.
https://seekingalpha.com/article/4133205-advaxis-2018-new-year-new-hope
I thought this article was reasonable. BF is watching our puppies get better.
"Advaxis's first revenue stream?
Some anticipated news has also come down the grapevine regarding one of ADXS's oldest commercial partners, Aratana Therapeutics (PETX). The two companies entered into a clinical collaboration in 2014, wherein ADXS licensed, among other agents, ADXS-HER2 for the treatment of canine osteosarcoma.
........
................. arguably most important, benefit for ADXS is the validation of the technology. The trial in dogs that led to the approval of the listeria-based therapy showed a near doubling of the median survival time. This represents perhaps the most impactful demonstration of efficacy that we've seen for a listeria-based therapy in cancer, and it definitely bodes well for the entire concept of listeria-based immunotherapy"
Sink or swim together. Management are just like us...shareholders.
Let's forget Adage and remember Amgen:
Under the terms of the deal, Amgen paid Advaxis $40 million upfront and purchased $25 million in Advaxis common stock. Amgen also funds clinical and commercial activities, and agreed to pay Advaxis up to $475 million in milestone payments, as well as royalty payments. In turn, Advaxis will lead the clinical development of its ADXS-NEO treatment and retain manufacturing responsibilities.
Other cash inflows coming also with other deals. I am hoping we stick by ADXS statement of good on cash til 2019. About $90 mill in bank was last number I recall.
I bought more at 3.04.
No worry, ADXS is AT -014 not AT PETX AT-016 "PETX AT-016 is a medical construct that was being tested for the treatment of canine osteoarthritis. The announcement today indicated it didn’t accomplish targeted trial outcomes.
PETX AT-014 is a medical construct targeting the treatment of canine osteosarcoma based on the ADXS HER2 Lm platform. Conditional approval for AT-014, from the USDA, is anticipated any day now.
Two very different initiatives not related in any way medically. AT-016 developed by VetStem Biopharma. AT-014 developed by Advaxis.
Hope that helps clear things up.
G.B. "
Barrier broken, I confess I bought more yesterday at 3.04 ;)
Great article and shows ADXS superiority. It could have been written today, yet it is 6/14. We need some acceleration. Thanks for great info, as always.
l like the one point "Aduro more toxic, less effective (vs Advaxis)"
True enough, you can simply sell your warrants. Volume seems low at the moment.
James,
On warrants, I called my broker and ADXSW are for strike of $5.00 share, expire 10/18. Why would you do that if you could simply buy at $3 ?
Yes, major buying opportunity. Loss takers may be short term issue, but I am keeping my eye on the key hole, not the door knob. Fundamentally ADXS is strong with big news milestones coming.
They just prey on biotechs during "waiting periods". They mark the calendar on Trials time periods and make sure they are not around when milestones hit. I think the lack of press in some regards is a means to not give away too much info to shorts.
Don't we have some other potential cash inflows from Amgen and a few other things?
A bargain! Buy your butt off. Just read the Jeffriess PPT or hear the suvivor stories. ADXS is still focused. It is a long trip, but worthwhile.
Re: ADXS-NEO has FDA Orphan, FDA Fast track, and EU Orphan status-
Hard to believe dipped below $3. Once the games are over and the stock players disappear, I feel the merit of the science/ IP will carry ADXS...rest will follow.
300 patents for LM going out to 2037 - Thank you James. Sometimes I only read your posts in order to stay relevant.
SEC needs to make sure there is a level playing field for individual stock holders. Part of game to be out there on the field with the big guys...sometimes feels powerless. We shall overcome too many positives on science that are trucking along.
While stock drops, good things happen...
"The forthcoming treatment from Aratana Therapeutics is a freeze-dried version of a vaccine studied by Dr. Nicola J. Mason at the University of Pennsylvania. While about 80 percent of dogs die within two years of an osteosarcoma diagnosis, the survival rate was 50 percent at three years in a pilot study of the vaccine in 18 dogs. As phase 3 of its osteosarcoma project, Morris is committing funding for a trial of the vaccine in 80 dogs."
Too much control by the big guys. Us little guys make or break with their moves. I think we see some great new institutes coming in real soon. It is too good a deal to pass up.
Re: Poster presentations are now on Advaxis website;
I like that James is "just the facts". Eye on the keyhole and not the doorknob.
How about a white knight? We need one big new player to come aboard and scoop up on this deal just by a big position. SP is a bargain while WE are down where we are. That vote of confidence with influence on new CEO and our solid science would make a lot of unhappy shareholders feel better. Buy out great, but it seems a big player could create there own gain just by buying in big. I say this is opportunity for another Tute.
I am majorly in! Almost all...Average 10 pos.
Anyone have an update on shorts?...they have to be going away...